Valmark Advisers Inc. Takes $233,000 Position in Cencora, Inc. (NYSE:COR)

Valmark Advisers Inc. bought a new stake in Cencora, Inc. (NYSE:COR) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 1,036 shares of the company’s stock, valued at approximately $233,000.

A number of other institutional investors have also modified their holdings of the business. Copperleaf Capital LLC increased its holdings in shares of Cencora by 11.2% in the 4th quarter. Copperleaf Capital LLC now owns 4,662 shares of the company’s stock valued at $1,047,000 after acquiring an additional 469 shares during the period. Allworth Financial LP increased its stake in Cencora by 43.7% in the 4th quarter. Allworth Financial LP now owns 2,403 shares of the company’s stock valued at $593,000 after buying an additional 731 shares during the period. Principal Securities Inc. increased its stake in Cencora by 11.9% in the 4th quarter. Principal Securities Inc. now owns 20,821 shares of the company’s stock valued at $4,678,000 after buying an additional 2,209 shares during the period. Everhart Financial Group Inc. increased its stake in Cencora by 2.0% in the 4th quarter. Everhart Financial Group Inc. now owns 3,076 shares of the company’s stock valued at $691,000 after buying an additional 61 shares during the period. Finally, Hickory Asset Management Inc. acquired a new position in Cencora in the 4th quarter valued at $572,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on COR. JPMorgan Chase & Co. boosted their price objective on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Wells Fargo & Company boosted their price objective on shares of Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 29th. Evercore ISI boosted their price objective on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Robert W. Baird upped their price target on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Finally, Barclays upped their price target on shares of Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $277.90.

Cencora Price Performance

Cencora stock opened at $241.37 on Wednesday. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $262.26. The company has a quick ratio of 0.53, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The firm’s 50-day simple moving average is $238.75 and its 200 day simple moving average is $237.41. The firm has a market capitalization of $46.65 billion, a PE ratio of 34.33, a P/E/G ratio of 1.49 and a beta of 0.49.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities research analysts predict that Cencora, Inc. will post 15.36 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Friday, February 14th will be given a $0.55 dividend. The ex-dividend date is Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.91%. Cencora’s dividend payout ratio is presently 31.29%.

Insider Buying and Selling at Cencora

In other Cencora news, Chairman Steven H. Collis sold 50,000 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $243.97, for a total value of $12,198,500.00. Following the transaction, the chairman now directly owns 326,557 shares in the company, valued at approximately $79,670,111.29. This represents a 13.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the transaction, the executive vice president now owns 20,329 shares in the company, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 10.80% of the stock is owned by insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.